BMJ guideline gives a weak recommendation to try non-inhaled medical cannabis for chronic pain | Research

The takeaway

An international clinical guideline issued a weak recommendation to offer non-inhaled medical cannabis for chronic cancer and non-cancer pain when standard treatments are insufficient, based on small improvements in pain, function, and sleep.

Chronic pain patients, prescribing clinicians, pain management specialists, health policy professionals

Weak recommendation to offer non-inhaled medical cannabis when standard care is insufficient

What the researchers found

The guideline panel issued a weak recommendation to offer a trial of non-inhaled medical cannabis or cannabinoids as add-on therapy for chronic pain when standard care is insufficient. This reflects small to very small improvements in pain intensity, physical functioning, and sleep quality, balanced against a small to modest risk of mostly self-limited harms.

Why it matters

This is one of the most rigorous clinical guidelines on medical cannabis for pain, providing a framework for shared decision-making between patients and clinicians based on the best available evidence.

The numbers in context

Weak recommendation; small to very small improvements in pain, function, and sleep; small to modest risk of mostly self-limited harms; non-inhaled forms recommended

How the study worked

International guideline developed using GRADE methodology with patient, clinician, and methodologist input, informed by four linked systematic reviews on benefits, harms, and patient values regarding medical cannabis for chronic pain.

What this study cannot tell us

Weak recommendation reflects close balance between benefits and harms. Evidence quality is variable. Further research may change the recommendation. Does not address inhaled cannabis.

How to read the evidence

GRADE-based international clinical practice guideline informed by four systematic reviews

When this study was published

Published in 2021. This guideline may be updated as new evidence emerges.

The bigger picture

This guideline lands in the middle of a contentious debate, acknowledging both the potential benefits and the limitations of cannabis for chronic pain while emphasizing individual patient preferences and shared decision-making.

Questions still open

Should inhaled forms be included in future guideline updates? Which specific cannabinoid formulations are most effective for different pain types? How should clinicians implement shared decision-making for medical cannabis?

Common questions

Does medical cannabis work for chronic pain?

This BMJ guideline found small to very small improvements in pain, function, and sleep from medical cannabis. The benefits are real but modest, and the panel issued a weak recommendation to try it when standard treatments are insufficient.

What form of medical cannabis is recommended for pain?

The guideline specifically recommends non-inhaled forms (such as oils, capsules, or sprays) rather than smoked or vaporized cannabis, as add-on therapy to standard pain management.

Read the original research

Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline.

BMJ (Clinical research ed.), 374, n2040

View on PubMed ↗Publisher’s paper ↗

Citation

Busse, Jason W; Vankrunkelsven, Patrick; Zeng, Linan; Heen, Anja Fog; Merglen, Arnaud; Campbell, Fiona; Granan, Lars-Petter; Aertgeerts, Bert; Buchbinder, Rachelle; Coen, Matteo; Juurlink, David; Samer, Caroline; Siemieniuk, Reed A C; Kumar, Nimisha; Cooper, Lynn; Brown, John; Lytvyn, Lyubov; Zeraatkar, Dena; Wang, Li; Guyatt, Gordon H; Vandvik, Per O; Agoritsas, Thomas. (2021). Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline.. BMJ (Clinical research ed.), 374, n2040. https://doi.org/10.1136/bmj.n2040